Stemtech Corporation (OTCQB:STEK), a leading innovator in patented stem cell nutrition health products, announces a significant milestone in its global expansion strategy with the signing of a license Agreement with an established direct sales company, based in Kenya.
The Agreement, effective January 29th, 2024, grants the license to purchase, use, market, and distribute Stemtech’s cutting-edge health related products within the designated Territory(s), including Kenya, Uganda, Tanzania, Ghana, Democratic Republic of Congo and Nigeria.
This strategic move represents Stemtech’s commitment to reaching new markets and introducing its patented stem cell nutrition, skin care and oral care products to new markets. The licensing agreement includes the distribution of StemRelease3™, StemFlo Advanced®, MigraStem™, OraStem™, and Cellect One™ Rapid Renew Stem Cell Peptide Night Cream.
John W. Meyer, President & COO of Stemtech Corporation, expressed excitement about the expansion, stating,
“We believe that this partnership marks a significant opportunity for Stemtech to establish brand recognition in key African markets and contribute to the overall health and wellness of the region.
We are confident that our stem cell nutrition products will make a positive impact and contribute to the growth of the wellness industry in Africa. Distributors will benefit from additional income for the current network marketers already engaged through